Skip to main content
Jan Brandes, MD, Neurology, Nashville, TN

JanLewisBrandesMDMS, FAAN, FAHS

Neurology Nashville, TN

Headache

Founder and Director, Nashville Neuroscience Group; Assistant Clinical Professor of Neurology, Vanderbilt University

Dr. Brandes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Brandes' full profile

Already have an account?

  • Office

    2315 GOLF CLUB LN
    Nashville, TN 37215
    Phone+1 615-516-0711

Summary

  • As the founder and director of Nashville Neuroscience Group, Jan Lewis Brandes, MD, MS, also holds an appointment as an Assistant Clinical Professor in the Department of Neurology at Vanderbilt University School of Medicine, Nashville, Tennessee. Prior to attending Vanderbilt University School of Medicine, where she subsequently earned her medical degree, Dr. Brandes attended the Robert Koch Institute of Virology, Free University in Berlin, Federal Republic of Germany, as a Fulbright Scholar. Her postgraduate medical training was completed at Vanderbilt University Medical Center where she served as chief resident in neurology. She also holds a Master of Science degree in microbiology from the University of Tennessee in Knoxville. She is certified by the National Board of Medical Examiners, The American Board of Psychiatry and Neurology and the National Board for Certification in Headache Management.

    Dr. Brandes has been active in clinical trials for more than two decades. She has served as the principal or co-principal investigator in more than st100 studies, primarily examining issues in migraine including acute treatment, prophylaxis and menstrual migraine. She has published extensively in peer-reviewed journals including JAMA, Cephalalgia, Headache, and Mayo Clinic Proceedings.

    Dr. Brandes is the immediate past chairman of Nashville Metro General Hospital Authority, a fellow of the American Headache Society and the American Academy of Neurology, and serves on the National Headache Foundation Board. She is a former member of the board of directors of the American Headache Society and is a past president of the American Council for Headache Education. In recognition of her professional endeavors, she has been named to Best Doctors in the Americas from 1996 to present.

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Neurology, 1990 - 1993
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterInternship, Internal Medicine, 1989 - 1990
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 1989
  • Robert Koch Institute of Virology
    Robert Koch Institute of VirologyFulbright Scholarship, Molecular Virology, 1982 - 1983
  • University of Tennessee
    University of TennesseeMS, Microbiology, subspecialty, herpes virology, 1977 - 1980
  • Mississippi University for Women
    Mississippi University for WomenBS, Biology, Cum Laude, 1975

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 1991 - 2026
  • American Board of Psychiatry and Neurology Neurology
  • United Council for Neurologic SubspecialtiesCertification in Headache Medicine

Awards, Honors, & Recognition

  • Lifetime Achievement Award National Headache Foundation, 2022
  • Fulbright Scholar Robert Koch Institute of Virology
  • Best Doctors in the Americas 1995-2018
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • ARISE: A Phase 3 Randomised Trial of Erenumab for Episodic Migraine  
    Dodick, D, Ashina, M., Brandes, J, Kudrow, D, Lanteri-Minet, M, Osipova, V, Palmer K, Picard, H, Mikol, D, Lenz R, Lancet Neurology
  • Safety and Efficacy of Erenumab for Preventive Treatment of Chronic Migraine: A Randomused, Double-Blind, Plecebo-Controlled Phase 2 Trial  
    Brandes JL, Tepper S, Ashina M, Reuter U, Lenz R, The Lancet Neurology, 1/1/2017
  • Sex Differences in the Study of Neurological Illnesses  
    Attarian H, Brandes JL, Dafer R, Giesser B, Behavioral Neurology, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Multiple-Attack Efficacy and Tolerability of Sumavel DosePro (needle-free subcutaneous sumatriptan) Among Current Triptan Users
    Brandes JL, Rothrock J, Cady R, Aurora S, Fox AW, Farr SJ, AAN Scientific Meeting, 1/1/2011
  • Randomized, Controlled Trial of Telcagepant in Acute Treatment of Migraine in Patients with Stable Coronary Artery Disease
    Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora S, Brandes JL, Fei K, Beebe L, Lines C, Krucoff M, Merck Research Laboratories, 1/1/2010
  • Migrainous Vertigo Presenting in the Perimenopause
    Brandes JL, Roberson S, Bennett M, Haynes D, 63nd Annual Meeting of the American Academy of Neurology, Toronto, 1/1/2010
  • Join now to see all

Lectures

  • The Neurological Examination 
    Vanderbilt University School of Medicine, Nashville, TN - 1/1/2017
  • Vestibular Headache/ Dysautonomia 
    Lake Buena Vista, FL - 1/1/2016
  • 25th Annual Practicing Physicians Approach to the Difficult Headache Patient 
    Diamond Headache Clinic Reseach and Educational Foundation, Rancho Mirage, California
  • Join now to see all

Other

Press Mentions

  • 5 of the Most Common Migraine Triggers
    5 of the Most Common Migraine TriggersJuly 13th, 2021
  • Nashville General Hospital Seeks $20M Boost to Annual City Subsidy
    Nashville General Hospital Seeks $20M Boost to Annual City SubsidyMarch 17th, 2017
  • FDA Approves Reyvow
    FDA Approves ReyvowOctober 13th, 2019